By Kyle Morris

AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.

The Anglo-Swedish pharma giant said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.

The trial will continue to assess overall survival as a key secondary endpoint, it said.

Breast cancer is the most common cancer in the world with an estimated 2.3 million patients diagnosed in 2020.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

October 26, 2022 02:30 ET (06:30 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca